Jimmy Wang - Albany Molecular CIO

Executive

Dr. Jimmy Wang, Ph.D., is Chief Information Officer of the Company. Dr. Wang brings 25 years of experience managing and deploying technology innovations to various technology, telecommunications and global pharmaceutical companies. Most recently he served as Senior Vice President and Chief Information Officer at OPKO Health Inc., where he established the company global IT governance process and transformed IT into a centralized delivery organization. Before OPKO Health, Dr. Wang was Senior Vice President and Chief Information Officer at Vertex Pharmaceuticals Inc., where he played a major role in managing implementation, consolidation, and support of Enterprise Operations Support Systems, as well as led the area of scientific computing to use technology to support the area of Innovation and Research. Before Vertex, Dr. Wang was at Teva PharmaceuticalsAmerica, where he was Vice President and Chief Information Officer since 2015.
Tenure 9 years
Professional MarksPh.D
Phone518 512-2000
Webwww.amriglobal.com
Wang received his Ph.D. in Operations Research from Southern Methodist University in 1990.

Albany Molecular Management Efficiency

The company has return on total asset (ROA) of (0.0657) % which means that it has lost $0.0657 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (22.1137) %, meaning that it created substantial loss on money invested by shareholders. Albany Molecular's management efficiency ratios could be used to measure how well Albany Molecular manages its routine affairs as well as how well it operates its assets and liabilities.
The company currently holds 647.96 M in liabilities with Debt to Equity (D/E) ratio of 204.3, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Albany Molecular Research has a current ratio of 0.67, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Albany Molecular until it has trouble settling it off, either with new capital or with free cash flow. So, Albany Molecular's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Albany Molecular Research sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Albany to invest in growth at high rates of return. When we think about Albany Molecular's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

EXECUTIVE Age

John MacMurraySaratoga Investment Corp
N/A
Nell JDP10 Inc
52
Kevin ShannonInflection Point Acquisition
N/A
Mark HoodP10 Inc
59
Ryan SwedburgEldorado Gold Corp
N/A
Denver HarrisSandstorm Gold Ltd
N/A
Per FrankEldorado Gold Corp
N/A
Nora LozanoEldorado Gold Corp
N/A
Peter OndishinInflection Point Acquisition
37
Richard JensenP10 Inc
52
Thomas JDSaratoga Investment Corp
N/A
Clayton WebbP10 Inc
43
Graham MorrisonEldorado Gold Corp
N/A
Rolando BondoyP10 Inc
N/A
KIM FORGAARDSandstorm Gold Ltd
N/A
Charles IVSaratoga Investment Corp
76
Lynette GouldEldorado Gold Corp
N/A
Christine GregorySandstorm Gold Ltd
70
QP MScSandstorm Gold Ltd
67
Claire ChamberlainEldorado Gold Corp
N/A
Andrew CorsiP10 Inc
N/A
Albany Molecular Research, Inc., a contract research and manufacturing company, offer integrated drug discovery, development, and manufacturing services primarily in the United States, Europe, and Asia. Albany Molecular Research (AMRI) is traded on NASDAQ Exchange in USA and employs 2,220 people.

Management Performance

Albany Molecular Research Leadership Team

Elected by the shareholders, the Albany Molecular's board of directors comprises two types of representatives: Albany Molecular inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Albany. The board's role is to monitor Albany Molecular's management team and ensure that shareholders' interests are well served. Albany Molecular's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Albany Molecular's outside directors are responsible for providing unbiased perspectives on the board's policies.
George Svokos, COO
Arthur Roth, Independent Director
Gerardo Gutierrez, Director
Thomas Ambra, Non-Executive Chairman of the Board
Lori Henderson, Vice President General Counsel, Secretary
Milton Boyer, Senior Vice President - Drug Product Manufacturing
Anthony Maddaluna, Director
Kenneth Hagen, Director
Fernando Napolitano, Director
Una Ryan, Lead Independent Director
David Deming, Director
Kevin Connor, Independent Director
Jimmy Wang, CIO
Gabriel Leung, Independent Director
Steven Hagen, Sr. VP of Manufacturing, Pharmaceuticals and Operations
Christopher Conway, Senior Vice President - Global Sales and Marketing
Felicia Ladin, CFO, Senior Vice President Treasurer
Veronica Jordan, Independent Director
William Marth, CEO and President and Director

Albany Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Albany Molecular a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Albany Molecular in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Albany Molecular's short interest history, or implied volatility extrapolated from Albany Molecular options trading.

Pair Trading with Albany Molecular

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Albany Molecular position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Albany Molecular will appreciate offsetting losses from the drop in the long position's value.
The ability to find closely correlated positions to DR Horton could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace DR Horton when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back DR Horton - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling DR Horton to buy it.
The correlation of DR Horton is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as DR Horton moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if DR Horton moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for DR Horton can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.
You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.

Other Consideration for investing in Albany Stock

If you are still planning to invest in Albany Molecular Research check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Albany Molecular's history and understand the potential risks before investing.
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk